Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Mallinckrodt to Pay $35M in Deal to End Feds’ Opioid Probe

By LINDA A. JOHNSON , AP Medical Writer | April 4, 2017

This Jan. 18, 2013, file photo shows a bottle of Morphine Sulfate, made by the pharmaceutical company Mallinckrodt PLC, in Carmichael, Calif. The Dublin, Ireland-based company, which sells a number of powerful opioid painkillers, has agreed to pay the U.S. government $35 million to resolve a probe of its distribution of those drugs. Mallinckrodt didn’t admit any wrongdoing, as is common with deals ending federal probes of companies. (AP Photo/Rich Pedroncelli)

 A top maker of brand-name and generic narcotic painkillers has agreed to pay the U.S. government $35 million to resolve a probe of its distribution of those drugs.

Mallinckrodt PLC said Monday it has reached an agreement with the U.S. Drug Enforcement Administration and the U.S. attorneys for the Eastern District of Michigan and Northern District of New York. The deal is subject to further review and approval by the DEA and Justice Department.

Mallinckrodt didn’t admit any wrongdoing, as is common with deals ending federal probes of companies.

Prosecutors and lawmakers have been investigating possible connections between marketing of addictive painkillers and the epidemic of opioid and heroin deaths.

Dublin, Ireland-based Mallinckrodt sells a number of powerful opioid painkillers including generic pills containing fentanyl, morphine and oxycodone. Its brand-name narcotic painkillers include extended-release Exalgo, Xartemis and Roxicodone pills. Mallinckrodt also makes medicines for treating narcotic addiction.

In a statement, Mallinckrodt said that its “innovative suspicious order monitoring program” exceeds DEA requirements.

Numerous companies that sell addictive opioid painkillers have been accused by politicians, lawyers and others of contributing to the U.S. epidemic of people who become addicted to the pills, often after having them prescribed following surgery or injury. Many eventually turn to much-cheaper heroin as a replacement.

More than 33,000 Americans died of an opioid overdose in 2015, the most of any year, according to the Centers for Disease Control and Prevention. Nearly half of the opioid overdose deaths involve a prescription opioid.

In one of the latest probes, Sen. Claire McCaskill, D-Missouri, last week began an investigation by seeking marketing information, sales records and studies from manufacturers of top-selling opioid products. She noted sales of prescription opioids have quadrupled since 1999.

President Donald Trump also promised to increase efforts to combat the opioid addiction crisis and picked New Jersey Gov. Chris Christie to head the project.


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE